Exagen

XGN · NASDAQ

$7.41−$0.02 (−0.27%)TodayMarket closed · Oct 20, 7:43 PM ET

Prev close $7.43

XGN analyst rating

BuyConsensus of 8 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy8
Hold0
Underperform0
Sell0

12-month price target · 8 analysts

Average $10.35 (+39.6% upside)

Low: $9.09
Now: $7.41
High: $12.60

Upgrades and downgrades

The latest rating actions, newest first

XGN analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Canaccord Genuity	Oct 19, 2026	Maintains	Buy	$9.00 → $11.00	55%
TD Cowen	Oct 13, 2026	Maintains	Buy	$10.00 → $11.00	50%
TD Cowen	Aug 5, 2026	Maintains	Buy	$8.00 → $10.00	61%
B. Riley Securities	Aug 5, 2026	Maintains	Buy	$8.00 → $12.00	53%
BTIG	Aug 5, 2026	Maintains	Buy	$8.00 → $9.00	54%
Roth Capital	Jun 25, 2026	Initiates	Buy	$8.00	36%
BTIG	May 12, 2026	Maintains	Buy	$9.00 → $8.00	54%
Canaccord Genuity	Apr 20, 2026	Maintains	Buy	$10.00 → $8.00	55%
Canaccord Genuity	Mar 11, 2026	Maintains	Buy	$15.00 → $10.00	55%
Craig-Hallum	Mar 11, 2026	Maintains	Buy	$12.00 → $10.00	57%

The case for and against

Updated Sep 1, 2026

Bull case

Exagen is poised for long-term success with its highly differentiated and in-demand testing products, solid volume growth and improving average selling prices (ASPs), and a focused sales strategy directed towards a specific targeted market. With its proven track record of consistently beating revenue estimates and positive developments in its pipeline, as well as a significantly undervalued stock price relative to its peers, it is clear that Exagen offers a strong value opportunity for investors looking to capitalize on the growing demand for accurate and efficient diagnostic testing in the medical field.

Bear case

Exagen is facing significant risks in terms of commercial execution, with potential challenges in securing reimbursement and payor acceptance for their products, as well as potential concentration risks with their focus on a single product. This, combined with their relatively small size and current lack of profitability, could pose challenges for the company's long-term success. Additionally, potential competition and regulatory risks could further hinder their growth and profitability. Overall, there are several fundamental factors that could negatively impact Exagen's stock performance in the future.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.